Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push
With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron, Parabilis Medicines has now turned its attention to the public markets.
With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron, Parabilis Medicines has now turned its attention to the public markets.